Profile

How many employees do you have, and how do you find/attract them? The company has about four full-time employees. Most of the employees were recruited by the cEo or cSo. What are the main focus and platform technology(ies) of your company? IMUc has been able to integrate several approaches to treating cancer into its platform technology. The company develops multi-targeted cancer immunotherapies that can eliminate cancer stem cells (cScs, aka tumor-initiating cells) in addition to normal bulk tumor cells. The technology also utilizes Il12-secreting dendritic cells (dcs) to elicit a highly potent immune response. The company's lead product (IcT-107) is currently in a multicenter, ran-domized, double-blind, placebo-controlled phase 2b trial for patients with newly diagnosed glioblastoma multiforme (GBM), a common and aggressive form of brain cancer. IMUc is also developing a cd133-targeted, therapeutic cancer vaccine (IcT-121); a phase 1 study with recurrent GBM patients is planned. Management also anticipates initiating a clinical trial for ovarian cancer with a third cancer vaccine (IcT-140). Who is your competition, and what advantage(s) does your products/technology offer? competitors include dendreon, Northwest Biotherapeutics, and Prima Biomed. Unlike most other cancer immunotherapy companies, IMUc focuses on developing treatments that target cScs as well as normal tumor cells. also, few immunotherapy companies develop treatments that target more than one tumor-associated antigen. What were the " highlights " in your recent development of vaccines/immunotherapeutics? results from a small, uncontrolled, single-center phase 1 study with IcT-107 in newly diagnosed GBM patients showed a survival benefit when compared with historical standard of care (Phuphanich et al. Cancer Immunol Immunother, PMId: 22847020). Median overall survival was 38.4 months (vs. 15.8 months for standard of care). Six of sixteen patients survived without any disease recurrence for more than three years. What have been the most critical problems in developing products in your field, and how can your company's technology help overcome these problems? The field of cancer immunotherapy has been characterized by several challenges. Many earlier products elicited relatively weak immune responses. In contrast, IMUc uses matured dcs, which secrete Il12, to elicit a potent immune response in patients. Il12 has been shown to be critical for activation of T-cell killing. What is your company's value proposition? IMUc has a library of several tumor-associated antigens, which can be mixed and matched to different types of solid tumors. Thus, the company's technology can potentially treat a wide variety of cancers. Management has also …